Characterization of a novel rat gene RTAP2a, screened by cross-reactive SEREX, restrictedly expressed in testis

Journal of Bioscience and Bioengineering

Volumn 107, Issue 6, 2009, Pages 589-595

  Yang, Hanshuo ^b   Wang, Chunting ^b   Wang, Rui ^b   Deng, Hongxin ^b   Ding, Zhenyu ^a,b   Yang, Jinliang ^b   Lu, You ^a,b   Li, Jiong ^b   Zhang, Peng ^c   Mao, Yongqiu ^b   Kan, Bing ^b   Wei, Lin ^b   Peng, Feng ^a,b   Wei, Yuquan ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c SICHUAN CANCER HOSPITAL   (China)

Author keywords

Cross reactive SEREX; RTAP2; SEREX; Splice variant; Testis

Indexed keywords

CROSS-REACTIVE SEREX; RTAP2; SEREX; SPLICE VARIANT; TESTIS;

AMINES; AMINO ACIDS; BIOINFORMATICS; CELL CULTURE; GENES; ORGANIC ACIDS; PROTEINS; TUMORS;

TRANSCRIPTION;

COMPLEMENTARY DNA; RAT TESTICULAR ANTIGENIC PROTEIN 2; RNA; RTAP2A PROTEIN; RTAP2B PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CROSS REACTION; DNA SEQUENCE; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RTAP2A GENE; SEROLOGICAL ANALYSIS OF RECOMBINANT CDNA EXPRESSION; SEROLOGY; TESTIS; TUMOR CELL; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; BASE SEQUENCE; CELL LINE, TUMOR; HUMANS; IMMUNOTHERAPY; MALE; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PROTEIN ISOFORMS; RATS; TESTICULAR NEOPLASMS; TESTIS;

RATTUS;

EID: 65649085310     PISSN: 13891723     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiosc.2009.02.005     Document Type: Article

References (30)

1. Rosenberg S.A. Progress in human tumor immunology and immunotherapy. Nature 411 (2001) 380-384
2. Wang R.F., and Rosenberg S.A. Human tumor antigens for cancer vaccine development. Immunol. Rev. 170 (1999) 85-100
3. Houghton A.N. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180 (1994) 1-4
4. Pfreundschuh M. Exploration of the B cell repertoire for the identification of human tumor antigens. Cancer Chemother. Pharmacol. 46 (2000) 3-7
5. Marincola F.M., Jaffe E.M., Hicklin D.J., and Ferrone S. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74 (2000) 181-273
6. Wei Y.Q. Immunotherapy of tumors with vaccines based on xenogeneic homologous molecules. Anticancer Drugs 13 (2002) 229-235
7. Neal Z.C., Bates M.K., Albertini M.R., and Herweijer H. Hydrodynamic limb vein delivery of a xenogeneic DNA cancer vaccine effectively induces antitumor immunity. Mol. Ther. 15 (2007) 422-430
8. Pupa S.M., Iezzi M., Di C., E., Invernizzi A., Cavallo F., Meazza R., Comes A., Ferrini S., Musiani P., and Menard S. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res. 65 (2005) 1071-1078
9. Kamstock D., Elmslie R., Thamm D., and Dow S. Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol. Immunother. 56 (2007) 1299-1309
10. He Q.M., Wei Y.Q., Tian L., Zhao X., Su J.M., Yang L., Lu Y., Kan B., Lou Y.Y., Huang M.J., Xiao F., Liu J.Y., and other 8 authors. Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J. Biol. Chem. 278 (2003) 21831-21836
11. Palomba M.L., Roberts W.K., Dao T., Manukian G., Guevara-Patiño J.A., Wolchok J.D., Scheinberg D.A., and Houghton A.N. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin. Cancer Res. 11 (2005) 370-379
12. Scanlan M.J., Gure A.O., Jungbluth A.A., Old L.J., and Chen Y.T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188 (2002) 22-32
13. Simpson A.J., Caballero O.L., Jungbluth A., Chen Y.T., and Old L.J. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 5 (2005) 615-625
14. Zendman A.J., Ruiter D.J., and Muijen Van G.N. Cancer/testis-associated genes: identification, expression profile, and putative function. J. Cell Physiol. 194 (2003) 272-288
15. De Smet C., De Backer O., Faraoni I., Lurquin C., Brasseur F., and Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 7149-7153
16. Gure A.O., Wei I.J., Old L.J., and Chen Y.T. The SSX gene family: characterization of 9 complete genes. Int. J. Cancer 101 (2002) 448-453
17. Stockert E., Jager E., Chen Y.T., Scanlan M.J., Gout I., Karbach J., Arand M., Knuth A., and Old L.J. A survey of the humoral response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 187 (1998) 1349-1354
18. Jager E., Nagata Y., Gnjatic S., Wada H., Stockert E., Karbach J., Dunbar P.R., Lee S.Y., Jungbluth A., Jager D., and other 7 authors. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 4760-4765
19. Davis I.D., Chen W., Jackson H., Parente P., Shackleton M., Hopkins W., Chen Q., Dimopoulos N., Luke T., Murphy R., and other 18 authors. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 10697-10702
20. Jager E., Gnjatic S., Nagata Y., Stockert E., Jäger D., Karbach J., Neumann A., Rieckenberg J., Chen Y.T., Ritter G., and other 4 authors. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 12198-12203
21. Sahin U., Türeci O., Schmitt H., Cochlovius B., Johannes T., Schmits R., Stenner F., Luo G., Schobert I., and Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 11810-11813
22. Nishikawa H., Tanida K., Ikeda H., Sakakura M., Miyahara Y., Aota T., Mukai K., Watanabe M., Kuribayashi K., Old L.J., and Shiku H. Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 14571-14576
23. Hansen M.H., Stenstad B., and Sioud M. Antigen-specific IgG antibodies in stage IV long-term survival breast cancer patients. Mol. Med. 7 (2001) 230-239
24. Hansen M.H., Stenstad B., and Sioud M. Identification of immunogenic antigens using a phage-displayed cDNA library from an invasive ductal breast carcinoma tumor. Int. J. Oncol. 19 (2001) 1303-1309
25. Kozak M. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 15 (1987) 8125-8148
26. Shimozawa N., Tsukamoto T., Nagase T., Takemoto Y., Koyama N., Suzuki Y., Komori M., Osumi T., Jeannette G., Wanders R.J., and Kondo N. Identification of a new complementation group of the peroxisome biogenesis disorders and PEX14 as the mutated gene. Hum. Mutat. 23 (2004) 552-558
27. Gavva N.R., Wen S.C., Daftari P., Moniwa M., Yang W.M., Yang-Feng L.P., Seto E., Davie J.R., and Shen C.K. NAPP2, a peroxisomal membrane protein, is also a transcriptional corepressor. Genomics 79 (2002) 423-431
28. Thomas J.W., Touchman J.W., Blakesley R.W., Bouffard G.G., Beckstrom-Sternberg S.M., Margulies E.H., Blanchette M., Siepel A.C., Thomas P.J., McDowell J.C., and other 61 authors. Comparative analyses of multispecies sequences from targeted genomic regions. Nature 424 (2003) 788-793
29. Amsterdam A., Nissen R.M., Sun Z., Swindell E.C., Farrington S., and Hopkins N. Identification of 315 genes essential for early zebrafish development. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 12792-12797
30. Shen Y.M., He X., Deng H.X., Yang H.S., Peng F., Xie Y., Wei Y.Q., and Zhao X. Expression of human Biot2 and its potential function on carcinogenesis in endometrial cancer. Acta Obstet. Gynecol. Scand. 86 (2007) 1503-1509